Gue, Y. X., Kanji, R., Wellsted, D. M., Srinivasan, M., Wyatt, S., & Gorog, D. A. (2019). Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study: A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. J Thromb Thrombolysis.

Gue, Ying X., Rahim Kanji, David M. Wellsted, Manivannan Srinivasan, Solange Wyatt, و Diana A. Gorog. "Rationale and Design of “Can Very Low Dose Rivaroxaban (VLDR) in Addition to Dual Antiplatelet Therapy Improve Thrombotic Status in Acute Coronary Syndrome (VaLiDate-R)” Study: A Randomised Trial Modulating Endogenous Fibrinolysis in Patients With Acute Coronary Syndrome." J Thromb Thrombolysis 2019.

Gue, Ying X., et al. "Rationale and Design of “Can Very Low Dose Rivaroxaban (VLDR) in Addition to Dual Antiplatelet Therapy Improve Thrombotic Status in Acute Coronary Syndrome (VaLiDate-R)” Study: A Randomised Trial Modulating Endogenous Fibrinolysis in Patients With Acute Coronary Syndrome." J Thromb Thrombolysis 2019.